ClinicalTrials.gg
RecruitingNCT03042988Updated Jan 16, 2026

Overnight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension

An interventional study of Heating pad and Sham control in Hypertension, Pure Autonomic Failure and Multiple System Atrophy, sponsored by Vanderbilt University Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2017; still recruiting 9 years 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Patients with autonomic failure are characterized by disabling orthostatic hypotension (low blood pressure on standing), and at least half of them also have high blood pressure while lying down (supine hypertension). Exposure to heat, such as in hot environments, often worsens their orthostatic hypotension. The causes of this are not fully understood. The purpose of this study is to evaluate whether applying local heat over the abdomen of patients with autonomic failure and supine hypertension during the night would decrease their nocturnal high blood pressure while lying down. This will help us better understand the mechanisms underlying this phenomenon, and may be of use in the treatment of supine hypertension.

Read the detailed description

Primary autonomic failure is a neurodegenerative condition characterized by loss of efferent sympathetic function and severe baroreflex impairment. The clinical hallmark of autonomic failure is disabling orthostatic hypotension, but at least half of patients are also hypertensive while lying down. This supine hypertension can be severe and associated with end-organ damage and worsening of orthostatic hypotension due to increased pressure natriuresis. It also complicates the management of these patients by limiting the use of daytime pressor agents for the treatment of orthostatic hypotension. Currently, no antihypertensive drug effectively lowers BP and prevents pressure natriuresis without worsening standing BP.

It is well known that heat exposure (e.g. hot weather or a hot bath or shower) produces an acute and temporary worsening of orthostatic hypotension in autonomic failure patients. Factors that may predispose these patients to the lowering BP effects of heat stress include 1) impaired heat dissipation due to inability to sweat, 2) preserved heat-mediated skin vasodilation, and 3) blunted sympathetic hemodynamic responses to maintain BP (increases in cardiac output, heart rate, and vaso- and venoconstriction). Our preliminary results showed that 2 hours of passive heat stress lowers BP in these patients through a decrease in central volume. In this study, we will assess the efficacy and safety of passive heat stress in the treatment of nocturnal supine hypertension in autonomic failure patients. Our hypothesis is that controlled local (abdominal) passive heat stress applied during the night will lower nocturnal BP in autonomic failure patients with supine hypertension.

To test this hypothesis, we propose to compare the BP effects of passive heat applied during the night vs. a sham control in a randomized crossover study in autonomic failure patients with supine hypertension.

02

Conditions studied

  • Hypertension
  • Pure Autonomic Failure
  • Multiple System Atrophy
  • Autonomic Failure

Keywords

  • supine hypertension
  • autonomic failure
  • heat stress
  • orthostatic hypotension
03

In context

Hypertension

6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.

This study's planned enrollment of 20 is below the median of 100 across 4,575 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Vanderbilt University Medical Center is the lead sponsor of 833 studies on the registry; 155 are open to participants now.

Of its 125 completed or terminated interventional studies of FDA-regulated products, 92 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients, between 18-80 yrs., with primary autonomic failure (Parkinson Disease, Multiple System Atrophy, and Pure Autonomic Failure) and supine hypertension. Supine hypertension will be defined as SBP≥150 mmHg.
  • Patients able and willing to provide .

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Significant cardiac, renal or hepatic illness, or with to administration of pressor agents or with other factors, which in the investigator's opinion would prevent the subject from completing the protocol including abnormalities in clinical, mental or laboratory testing.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Heat Stress

    Passive heat-stress using a commercial heating pad applied on the trunk

    Other: Heating pad

  • Sham comparator
    Control (Non-heating)

    Commercial heating pad applied on the trunk but turned off

    Other: Sham control

Interventions

  • OtherHeating pad

    Heat stress applied on the trunk for up to 8 hours

    Also known as: Local heat stress

  • OtherSham control

    heating pad turned off applied on the trunk for up to 8 hours

    Also known as: control

06

What researchers measure

Primary outcomes

  1. Systolic blood pressure

    Maximal change from baseline in systolic blood pressure during the night, measured from 10 pm to 8 am

    Time frame: 10 pm - 8 am

Secondary outcomes

  1. Orthostatic Tolerance the following morning

    Orthostatic tolerance defined as the area under the curve of standing systolic blood pressure calculated by the trapezoidal rule (upright systolic blood pressure multiplied by standing time) during a 10-minute standing test

    Time frame: 10 min standing

07

Study locations

1 of 1 sites recruiting
  • Autonomic Dysfunction Center/ Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
    Recruiting
    • Emily C Smith, RN · Contactautonomics@vumc.org · 615.875.1516
    • Bonnie K Black, RN · Contactautonomics@vumc.org · 615-322-3304
    • Bonnie K Black, RN · Sub investigator
    • Luis E Okamoto, MD · Sub investigator
    • David Robertson, MD · Sub investigator
    • Italo Biaggioni, MD · Principal investigator
    • Alfredo Gamboa, MD · Sub investigator
    • Cyndya A Shibao, MD · Sub investigator
    • Andre Diedrich, MD, PhD · Sub investigator
    • jorge Celedonio, MD · Sub investigator
    • Emily C Smith, RN · Sub investigator
08

References and documents

Publications

  • Okamoto LE, Celedonio JE, Smith EC, Gamboa A, Shibao CA, Diedrich A, Paranjape SY, Black BK, Muldowney JAS 3rd, Peltier AC, Habermann R, Crandall CG, Biaggioni I. Local Passive Heat for the Treatment of Hypertension in Autonomic Failure. J Am Heart Assoc. 2021 Apr 6;10(7):e018979. doi: 10.1161/JAHA.120.018979. Epub 2021 Mar 19. PubMed 33739123 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2017 (actual). Primary completion is estimated for Nov 2026, 118 months after the start.

Of 1,403 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 118 months is above that.

Counting every sponsor, half of 1,498 studies reached it within 23 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2017
First posted
Feb 3, 2017
StartActual
Jan 30, 2017
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03042988
Responsible party
Italo Biaggioni (Professor of Medicine and Pharmacology, Vanderbilt University Medical Center) — Principal investigator
First posted
Feb 3, 2017
Start date
Jan 30, 2017
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jan 16, 2026

Study contacts

Bonnie K Black, RN
Contact
autonomics@vumc.org
615-343-6862
Italo Biaggioni, MD
Contact
autonomics@vumc.org
Italo Biaggioni, MD
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion